ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, Dominique L. Monnet, Head of Programme Antimicrobial Resistance & Healthcare-associated Infections (ARHAI) (ECDC)
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Amanda Mocroft, UCL
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Combining risk assessment and value chain frameworksILRI
Presentation by Theo Knight-Jones at a stakeholder workshop on risk analysis in the Borena-Nazareth-Djibouti livestock value chain, Addis Ababa, Ethiopia, 11-14 August 2015.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Karen Champenois, Maison Blanche Hospital, Paris
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Amanda Mocroft, UCL
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Combining risk assessment and value chain frameworksILRI
Presentation by Theo Knight-Jones at a stakeholder workshop on risk analysis in the Borena-Nazareth-Djibouti livestock value chain, Addis Ababa, Ethiopia, 11-14 August 2015.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Karen Champenois, Maison Blanche Hospital, Paris
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sophocles Chanos
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Trends on Health-Care Associated Infections and Infection Control in Estonia ...Kazimierz Murzyn
Presentation given during Cost AMiCI meeting in Tallinn Nov 2017
by Pille Märtin
Infection control doctor
West-Tallinn Central Hospital
Chief specialist
Dep. Of Communicable Diseases surveillance and control
Health Board of Estonia
After several years of decreasing trend, foodborne hepatitis A virus (HAV) infection has re-emerged as a public health problem in EU/EEA since 2011. Several consecutive multi-country foodborne HAV outbreaks were experienced in Europe 2012-2014.
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo HauptKylieOBrien10
Research Manager Dr. Riccardo Haupt presented the PanCareSurPass project at the ‘PanCare and ELTEC – Late effects’ session of the SIOP Europe/CCI Europe Meeting 2021 on 28th April 2021.
PanCareSurPass has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 89999. The material presented and views expressed here are the responsibilities of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
DRIVE annual forum 2019, Helsinki, Finland, 17th-18th September
Development of Robust and Innovative Vaccine Effectiveness
Increasing understanding of influenza vaccine effectiveness in Europe
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
Findings from the joint report Tuberculosis surveillance and monitoring in Europe by ECDC and WHO Regional Office for Europe
More Related Content
Similar to ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, Dominique L. Monnet, Head of Programme Antimicrobial Resistance & Healthcare-associated Infections (ARHAI) (ECDC)
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sophocles Chanos
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Trends on Health-Care Associated Infections and Infection Control in Estonia ...Kazimierz Murzyn
Presentation given during Cost AMiCI meeting in Tallinn Nov 2017
by Pille Märtin
Infection control doctor
West-Tallinn Central Hospital
Chief specialist
Dep. Of Communicable Diseases surveillance and control
Health Board of Estonia
After several years of decreasing trend, foodborne hepatitis A virus (HAV) infection has re-emerged as a public health problem in EU/EEA since 2011. Several consecutive multi-country foodborne HAV outbreaks were experienced in Europe 2012-2014.
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo HauptKylieOBrien10
Research Manager Dr. Riccardo Haupt presented the PanCareSurPass project at the ‘PanCare and ELTEC – Late effects’ session of the SIOP Europe/CCI Europe Meeting 2021 on 28th April 2021.
PanCareSurPass has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 89999. The material presented and views expressed here are the responsibilities of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
DRIVE annual forum 2019, Helsinki, Finland, 17th-18th September
Development of Robust and Innovative Vaccine Effectiveness
Increasing understanding of influenza vaccine effectiveness in Europe
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
Similar to ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, Dominique L. Monnet, Head of Programme Antimicrobial Resistance & Healthcare-associated Infections (ARHAI) (ECDC) (20)
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
HIV transmission remains a major public health concern and affects more than 2 million people in the WHO European Region.
These ECDC slides summarise findings from the report which is available via http://bit.ly/WAD_18
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
More from European Centre for Disease Prevention and Control (20)
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, Dominique L. Monnet, Head of Programme Antimicrobial Resistance & Healthcare-associated Infections (ARHAI) (ECDC)
1. ECDC ARHAI networks:
achievements in 2013-2014 and challenges
for 2015-2016
Dominique L. Monnet, Head of Programme
Antimicrobial Resistance & Healthcare-associated Infections (ARHAI)
Stockholm, 11-13 February 2015
3. Antimicrobial Resistance and Healthcare-
Associated Infections (1)
Office of the Chief Scientist
. Disease Programme Section
– Dominique L. Monnet, Head of Disease Programme
– Barbara Albiger, Programme manager
– Elmira Khazeeva, Secretary
Surveillance and Response Support Unit
. Surveillance Section
– Ole E. Heuer, Senior Expert AMR surveillance, Group Leader
– Liselotte Diaz Högberg, Expert AMR surveillance
– Klaus Weist, Senior Expert Antimicrobial consumption surveillance
– Carl Suetens, Senior Expert HAI surveillance
– Jolanta Griškevičienė, Expert HAI surveillance
– Pete Kinross, Expert HAI surveillance
– To be recruited, Senior Expert AMR & HAI
. Scientific Assessment Section
– Anna-Pelagia Magiorakos, Senior Expert AMR & HAI
– Alessandro Cassini, Expert AMR & HAI
. Epidemic Intelligence and Response Section
– Diamantis Plachouras, Expert AMR & HAI
4. Surveillance and Response Support Unit (continued)
. Epidemiological Methods Section
– Daniel Palm, Senior Expert
– Karin Johansson, Expert
Public Health Capacity and Communication Unit
. Public Health Training Section
– Carmen Varela, Senior Expert and Group Leader, Training Network Strenghtening
– Vladimir Prikazsky, Expert
. External Communication Section
– Sarah Earnshaw, Group Leader, Press, Media and Information
– Giovanni Mancarella, Communciation Officer
– Andrea Mendez, Communication Specialist
– Karen Aimard, Communication Officer
– Andrea Würz, Communciation Officer
– Boyana Todorova, Communication Officer
Office of the Director, International Relations Section
– Nabil Safrany, International Relations Officer
Antimicrobial Resistance and Healthcare-
Associated Infections (2)
5. Austria
Federal Ministry of
Health
Greece
Hellenic Centre for Dis.
Control and Prev.
Norway
Norwegian Institute of
Public Health
Belgium
Scientific Institute of
Public Health
Hungary
National Center for
Epidemiology
Poland
Nat. Inst. of Public Health
– Nat. Inst. of Hygiene
Bulgaria
National Centre of
Infectious and
Parasitic Diseases
Iceland
Centre of Health
Security and Comm.
Disease Prevention
Portugal
Directorate General of
Health
Croatia
Croatian Nat. Inst.
of Public Health
Ireland
Health Protection
Surveillance Centre
Romania
National Institute of
Public Health
Cyprus
Directorate of
Medical and Public
Health Services
Italy Ministry of Health Slovakia
Public Health Authority of
the Slovak Republic
Czech
Republic
National Institute of
Public Health
Latvia
Centre for Disease Prev.
and Control
Slovenia
National Institute of
Public Health
Denmark
Danish Health and
Medicines Authority
Lichtenstein
Principality of
Liechtenstein
Spain
Ministry of Health, Social
Services and Equality
Estonia Health Board Lithuania Ministry of Health Sweden
Public Health Agency of
Sweden
Finland
National Institute for
Health and Welfare
Luxembourg Health Directorate
United
Kingdom
Public Health England
(Colindale)
France
Institute for Public
Health Surveillance
Malta
Superintendence of
Public Health
Germany
Robert Koch
Institute
Netherlands
National Institute for
Public Health and the
Environment
List of nominated
Coordinating Competent Bodies (CCBs)
Source: ECDC, 2015.
8. Disease Network Coordination Committees
(DNCCs), 2015-2018
• Results after elections, by alphabetical order
• Enter in function for Joint DNCC Meeting, 14-15 April 2015
• EARS-Net
José Campos, Tim Eckmanns, Vincent Jarlier, Alan Johnson,
Jos Monen, Annalisa Pantosti, Gunnar Skov Simonsen,
Alkiviadis Vatopoulos, Dorota Żabicka, Helena Žemličková
• ESAC-Net
Marcel Bruch, Philippe Cavalié, Herman Gossens, Jenny Hellman,
Susan Hopkins, Stephanie Natsch, Anna Olczak-Pieńkowska,
Ajay Oza, Arjana Tambić, Peter Zarb
• HAI-Net*
Aleksander Deptuła, Petra Gastmeier, Mayke Koek, Jana Kolman,
Outi Lyytikäinen, Maria Luisa Moro, Mercedes Palomar, Jacqui Reilly,
Anne Savey, Reinhild Strauss, Rolanda Valintėlienė
*Due to an equal number of votes, the HAI-Net CC is exceptionally composed of 11 (instead of 10) members.
9. Indicators
Epidemic intelligence
Coordination
Ongoing surveillance
Ad-hoc studies / projects
Point prevalence survey
Risk assessment : syst.
reviews and guidance
Communication
Training
ECDC Antimicrobial Resistance and Healthcare-
Associated Infections Programme, 2007-2015
EARS-Net ESAC-Net HAI-Net
EuSCAPE, LA-MRSA
Contribution to WHO
Hand Hygiene Day
European Antibiotic Awareness Day
Interactive database
& Reports
Point prevalence survey of HAI and antimicrobial use
in acute care hospitals (2nd PPS in 2016-2017)
Infection control
indicators (2015)
Antibiotic stewardship
indicators (2015)
HAI LTCFs, CDI surv.
Hosp. IPC prog.
Infection control
training (TRICE-IS)
Coord. Committee Coord. Committee
Joint Meetings of ARHAI Networks
Short course on prevention and control of MDROs
Periop. prophylaxis
EPIS AMR-HAIEPIS AMR-HAI
Interactive database
& Annual report
Interactive database
& Annual report
CPE, ESBL
Inter-agency report - JIACRA (2014)
Directory of online resources for infection prevention and control (2015)
Coord. Committee
Hosp. use (2015)
Burden of HAI & AMR(2015)
Source: ECDC, 2015.
11. 2013-2014
• EARS-Net: annual reports, updates of interactive database,
EQA exercise
• ESAC-Net: reports and updates of interactive database
• HAI-Net:
• Point prevalence survey of HAI and antimicrobial use, 2011-2012:
report and interactive database, trainings, validation in 4 countries
• Surgical site infections: 2010-2011 report
• HAI and antimicrobial use in long-term care facilities (HALT) reports,
2010 & 2013
• Feasibility study for EU surveillance of Clostridium difficile infection
• Support to standardisation of antimicrobial
susceptibility testing methods and clinical breakpoints
for surveillance of antimicrobial resistance
Surveillance activities (1)
12. 2015-2016
• EARS-Net: annual reports, updates of interactive database, EQA
• ESAC-Net: report 2013-2014, updates of interactive database,
start of hospital antimicrobial consumption surveillance
• HAI-Net:
- HAI in intensive care units: 2008-2012 report (2015, in press)
- Surgical site infections: 2012 & 2013 reports
- HAI and antimicrobial use in long-term care facilities (3rd PPS)
- Start of Clostridium difficile infection surveillance (2016)
- Prep. (2015), then start 2nd PPS in acute care hospitals (2016)
- Introduction of structure & process indicators: PPS, ICU
• Support to standardisation of antimicrobial
susceptibility testing methods and clinical breakpoints for
surveillance of antimicrobial resistance
Surveillance activities (2)
14. • Surveillance Atlas of Infectious Diseases:
integration of EARS-Net, ESAC-Net and HAI-Net data
• Link data across the three networks, at hospital level
• Burden (deaths and costs) of HAIs and AMR
updated estimates for the EU and by country
• Introduce structure and process indicators
• Improve country participation in HAI surveillance:
all EU/EEA Member States, validated data (PPS)
Surveillance activities (3)
15. 2013-2014
• Interim results from the European survey on
carbapenemase-producing Enterobacteriaceae (EuSCAPE)
project 2013
2015-2016
• EuSCAPE: final report (2015)
• Self-assessment and evaluation (post-EuSCAPE, 2015)
• Livestock-associated MRSA survey (2015)
• Survey on molecular typing of carbapenem-resistant
Enterobacteriaceae in Europe (preparatory work with
consultations of experts in 2015)
Ad-hoc studies/surveys
16. 2013-2014
• Epidemic Intelligence Information System (EPIS)
for AMR and HAI events
• Country visit to discuss AMR and HAI issues (Portugal)
2015-2016
• Open the EPIS platform to all members of EARS-Net,
ESAC-Net and HAI-Net, i.e. All nominated National Focal
Points and Operational Contact Points
• Country visits to discuss AMR and HAI issues
- Invitations from Spain and Cyprus
- Budget for 2-3 visits / year
• Unexpected requests
Epidemic intelligence and
response support activities
17. 2013-2014
• Perioperative antibiotic prophylaxis (systematic review and guidance)
• Triazole-resistant Aspergillus spp. (risk assessment)
• Infection control measures to prevent the transmission of
ESBL-producing Enterobacteriaceae and of carbapenemase-
producing Enterobacteriaceae (2 systematic reviews)
• Healthcare-associated MRSA (systematic review)
Köck R, et al. Euro Surveill 2014 Jul 24;19(29). pii: 20860.
2015-2016
• Organisation of hospital infection control programmes
Zingg W, et al. Lancet Infect Dis 2015; 15(2): 212-24.
• Precautions for patients being transferred between
healthcare institutions across borders (guidance)
• ECDC directory of online resources (& toolbox)
Systematic reviews and guidance
documents
20. 2013-2014
• Core competencies for infection control and hospital hygiene
professionals in the European Union
• Training infection control and hospital hygiene
professionals in Europe (2 articles)
Brusaferro S, et al. Euro Surveill. 2014 Dec 11;19(49). pii: 20985.
Brusaferro S, et al. J Hosp Infect 2015. In press.
2015-2016
• Short course on control of multidrug-resistant
organisms (MDROs) in healthcare settings (20-22 Jan. 2015)
• Evaluation of existing national courses against the
core competencies (2015)
• Field Epidemiology Manual Wiki for infection control and
hospital hygiene (2016)
Public health training activities
22. 2014
• European Antibiotic Awareness Day: a five-year perspective of Europe-
wide actions to promote prudent use of antibiotics.
Euro Surveill 2014 Oct 16;19(41). pii: 20928.
• 17 November: Event at ECDC, with the Public Health Agency of Sweden
• 18 November: >40 European countries, together with WHO/Europe
• 18 November: Global reach through collaboration with the U.S., Canada
and Australia and WHO Regional Offices
• #EAAD: >4000 tweets, 14 million impressions;
#AntibioticDay: >6000 tweets, 41 million impr.
2015-2016
• European Antibiotic Awareness Day, 18 Nov.
• Technical Advisory Committee + Meetings with experts
• New materials & toolkit (tbd)
• European event and social media activities
• Contribution to global awareness activities on 18 November
European Antibiotic Awareness Day
24. Support to the Commission
2013-2014
• Regular teleconferences
• Contribution to 2nd report on the implementation
of Council Recommendation 2009/C 151/01
• Contribution to progress report on the
implementation of the Commission’s 5-year
action plan (in press)
2015-2016
• Regular teleconferences
• Support on the implementation of the
Commission’s 5-year action plan
• Evaluation of the implementation of Council
Recommendation 2002/77/EC
• Other actions in action plan
25. 2013-2014
• European Food Safety Authority (EFSA) & ECDC.
European Union Summary Report on antimicrobial resistance in
zoonotic and indicator bacteria from humans, animals and food
in 2012 http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-in-
zoonotic-and-indicator-bacteria-summary-report-2012.pdf
• European Medicines Agency (EMA) Antimicrobial Advice
Ad Hoc Expert Group (AMEG). Use of antibiotics in animals:
impact on public health and animal health. http://www.ema.europa.eu
(Regulatory > Veterinary medicines >
Antimicrobial resistance > Use of antibiotics in animals)
• EMA. Sales of veterinary antimicrobial agents in 26 EU/EEA
countries in 2012. Fourth ESVAC Report. http://www.ema.europa.eu
(Regulatory > Veterinary medicines > Antimicrobial resistance > European Surveillance of
Veterinary Antimicrobial Consumption)
• ECDC/EFSA/EMA. Joint Interagency Antimicrobial Consumption
and Resistance Analysis (JIACRA) Report (30 January 2015)
http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-JIACRA-report.pdf
Collaboration with other EU agencies
26. 2013-2014
• Contribution to Global report on surveillance of AMR
• Contribution to WHO/Europe´s strategic action plan on AMR
• See below
2015-2016
• Regular teleconferences
• Contribution to Global Action Plan on AMR
• Contribution to WHO “SAVE LIVES: Clean Your Hands”
campaign, 5 May
• Collaboration on surveillance of AMR
(meetings of WHO/Europe’s CAESAR, AGISAR, WHO/HQ expert
consultation) and antimicrobial consumption
• Collaboration on European Antibiotic Awareness Day
• Possible joint country visits
Collaboration with WHO
27. Source: CDC, 2015 (http://www.cdc.gov/drugresistance/tatfar/).
2015-2016
• Process for transatlantic communication
of critical events – new AMR trends
• Indicators for hospital antimicrobial
stewardship programmes
• Standards for measuring antimicrobial
use in hospitals
28. 3rd Joint Meeting of the ARHAI Networks,
Stockholm, 11-13 February 2015
• Network sessions
EARS-Net, ESAC-Net, HAI-Net
• Dinner at hotel (today 11/2)
• Plenary session organised
by the Public Health Agency
of Sweden (Thursday 12/2 pm)
• Dinner organised jointly with the
Swedish Ministry of Health and
Social Affairs (12/2)
• Final plenary session
(Friday 13/2, 11:30-13:30)
• Lunch & departure
• Slides (SlideShare) & evaluation